Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting predominantly the dopaminergic mesotelencephalic system. Enormous progress has been made in the treatment of PD. Our previous study has shown that hydroxysafflor yellow A (HSYA) could attenuate the neurotoxicity indu...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 2013-08, Vol.714 (1-3), p.83-88 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 88 |
|---|---|
| container_issue | 1-3 |
| container_start_page | 83 |
| container_title | European journal of pharmacology |
| container_volume | 714 |
| creator | Han, Bing Hu, Jia Shen, Jingyu Gao, Yonglin Lu, Yan Wang, Tian |
| description | Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting predominantly the dopaminergic mesotelencephalic system. Enormous progress has been made in the treatment of PD. Our previous study has shown that hydroxysafflor yellow A (HSYA) could attenuate the neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. In the present work, we examined whether HSYA had the neuroprotective effect on dopaminergic neurons of substantia nigra in a rat model of PD. Adult Sprague-Dawley rats were unilaterally injected with 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle. The PD rats were treated with HSYA (2 or 8mg/kg) via caudal vein injection daily for 4 weeks. Rotational tests showed that HSYA significantly attenuated apomorphine-induced turns in 6-OHDA-induced PD rats. HSYA treatment resulted in a significant protection against the loss of tyrosine hydroxylase-positive cells. Our data showed that HSYA also increased the levels of dopamine and its metabolites, glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor in striatum of PD rats. In conclusion, these results supported a role for HSYA in preserving dopamine neuron integrity and motor function in a rodent model of PD, and implied a potential neuroprotective role for HSYA in this disease. |
| doi_str_mv | 10.1016/j.ejphar.2013.06.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1660410609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299913004779</els_id><sourcerecordid>1660410609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-3d16e4b07b28b0097977568734f351f99a7bd272ee9de96bd567f68d132ed3173</originalsourceid><addsrcrecordid>eNqFkU2PFCEQQInRuOPqPzDKTS_dUkDDcDHZbPxKNmqieyZ0U7i0M80I3avz72XTo0c9FUm9KqrqEfIUWAsM1KuxxfFw43LLGYiWqZYB3CMb2GrTMA38PtkwBrLhxpgz8qiUkTHWGd49JGdcaAMK5IaMH3HJ6ZDTjMMcb5FiCPVFU6A3R5_Tr2NxIexSpkfc7dJPekHTRFVzSvp0cPs4YRMnvwzo6WeXv8eppOlFoT4WdAVpnGh2c3lMHgS3K_jkFM_J9ds3Xy_fN1ef3n24vLhqBrnt5kZ4UCh7pnu-7Rkz2mjdqa0WMogOgjFO955rjmg8GtX7Tumgth4ERy9Ai3Pycu1bt_qxYJntPpahTu8mTEuxoBSTwBQz_0clN0oYwWVF5YoOOZWSMdhDjnuXjxaYvRNiR7sKsXdCLFO2Cqllz04_LP0e_d-iPwYq8HwFgkvWfcux2OsvtUNXbUmoi1fi9UpgPdptxGzLEHGq1465qrI-xX_P8Bv2d6ea</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1429639324</pqid></control><display><type>article</type><title>Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Han, Bing ; Hu, Jia ; Shen, Jingyu ; Gao, Yonglin ; Lu, Yan ; Wang, Tian</creator><creatorcontrib>Han, Bing ; Hu, Jia ; Shen, Jingyu ; Gao, Yonglin ; Lu, Yan ; Wang, Tian</creatorcontrib><description>Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting predominantly the dopaminergic mesotelencephalic system. Enormous progress has been made in the treatment of PD. Our previous study has shown that hydroxysafflor yellow A (HSYA) could attenuate the neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. In the present work, we examined whether HSYA had the neuroprotective effect on dopaminergic neurons of substantia nigra in a rat model of PD. Adult Sprague-Dawley rats were unilaterally injected with 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle. The PD rats were treated with HSYA (2 or 8mg/kg) via caudal vein injection daily for 4 weeks. Rotational tests showed that HSYA significantly attenuated apomorphine-induced turns in 6-OHDA-induced PD rats. HSYA treatment resulted in a significant protection against the loss of tyrosine hydroxylase-positive cells. Our data showed that HSYA also increased the levels of dopamine and its metabolites, glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor in striatum of PD rats. In conclusion, these results supported a role for HSYA in preserving dopamine neuron integrity and motor function in a rodent model of PD, and implied a potential neuroprotective role for HSYA in this disease.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2013.06.011</identifier><identifier>PMID: 23791614</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>3,4-Dihydroxyphenylacetic Acid - metabolism ; adults ; animal models ; Animals ; Apomorphine - pharmacology ; Behavior, Animal - drug effects ; Brain-derived neurotrophic factor ; Chalcone - analogs & derivatives ; Chalcone - pharmacology ; dopamine ; Gene Expression Regulation, Enzymologic - drug effects ; Glial cell line-derived neurotrophic factor ; Homovanillic Acid - metabolism ; Hydroxysafflor yellow A ; Male ; metabolites ; mice ; Neostriatum - drug effects ; Neostriatum - metabolism ; neurons ; Neuroprotective Agents - pharmacology ; neuroprotective effect ; neurotoxicity ; Oxidopamine ; Parkinson disease ; Parkinson Disease - metabolism ; Parkinson Disease - prevention & control ; Parkinson's disease ; Quinones - pharmacology ; Rats ; Rats, Sprague-Dawley ; Rotation ; Substantia Nigra - drug effects ; Substantia Nigra - metabolism ; tyrosine ; Tyrosine 3-Monooxygenase - metabolism</subject><ispartof>European journal of pharmacology, 2013-08, Vol.714 (1-3), p.83-88</ispartof><rights>2013 Elsevier B.V.</rights><rights>Copyright © 2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-3d16e4b07b28b0097977568734f351f99a7bd272ee9de96bd567f68d132ed3173</citedby><cites>FETCH-LOGICAL-c485t-3d16e4b07b28b0097977568734f351f99a7bd272ee9de96bd567f68d132ed3173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014299913004779$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23791614$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Han, Bing</creatorcontrib><creatorcontrib>Hu, Jia</creatorcontrib><creatorcontrib>Shen, Jingyu</creatorcontrib><creatorcontrib>Gao, Yonglin</creatorcontrib><creatorcontrib>Lu, Yan</creatorcontrib><creatorcontrib>Wang, Tian</creatorcontrib><title>Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting predominantly the dopaminergic mesotelencephalic system. Enormous progress has been made in the treatment of PD. Our previous study has shown that hydroxysafflor yellow A (HSYA) could attenuate the neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. In the present work, we examined whether HSYA had the neuroprotective effect on dopaminergic neurons of substantia nigra in a rat model of PD. Adult Sprague-Dawley rats were unilaterally injected with 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle. The PD rats were treated with HSYA (2 or 8mg/kg) via caudal vein injection daily for 4 weeks. Rotational tests showed that HSYA significantly attenuated apomorphine-induced turns in 6-OHDA-induced PD rats. HSYA treatment resulted in a significant protection against the loss of tyrosine hydroxylase-positive cells. Our data showed that HSYA also increased the levels of dopamine and its metabolites, glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor in striatum of PD rats. In conclusion, these results supported a role for HSYA in preserving dopamine neuron integrity and motor function in a rodent model of PD, and implied a potential neuroprotective role for HSYA in this disease.</description><subject>3,4-Dihydroxyphenylacetic Acid - metabolism</subject><subject>adults</subject><subject>animal models</subject><subject>Animals</subject><subject>Apomorphine - pharmacology</subject><subject>Behavior, Animal - drug effects</subject><subject>Brain-derived neurotrophic factor</subject><subject>Chalcone - analogs & derivatives</subject><subject>Chalcone - pharmacology</subject><subject>dopamine</subject><subject>Gene Expression Regulation, Enzymologic - drug effects</subject><subject>Glial cell line-derived neurotrophic factor</subject><subject>Homovanillic Acid - metabolism</subject><subject>Hydroxysafflor yellow A</subject><subject>Male</subject><subject>metabolites</subject><subject>mice</subject><subject>Neostriatum - drug effects</subject><subject>Neostriatum - metabolism</subject><subject>neurons</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>neuroprotective effect</subject><subject>neurotoxicity</subject><subject>Oxidopamine</subject><subject>Parkinson disease</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson Disease - prevention & control</subject><subject>Parkinson's disease</subject><subject>Quinones - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Rotation</subject><subject>Substantia Nigra - drug effects</subject><subject>Substantia Nigra - metabolism</subject><subject>tyrosine</subject><subject>Tyrosine 3-Monooxygenase - metabolism</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2PFCEQQInRuOPqPzDKTS_dUkDDcDHZbPxKNmqieyZ0U7i0M80I3avz72XTo0c9FUm9KqrqEfIUWAsM1KuxxfFw43LLGYiWqZYB3CMb2GrTMA38PtkwBrLhxpgz8qiUkTHWGd49JGdcaAMK5IaMH3HJ6ZDTjMMcb5FiCPVFU6A3R5_Tr2NxIexSpkfc7dJPekHTRFVzSvp0cPs4YRMnvwzo6WeXv8eppOlFoT4WdAVpnGh2c3lMHgS3K_jkFM_J9ds3Xy_fN1ef3n24vLhqBrnt5kZ4UCh7pnu-7Rkz2mjdqa0WMogOgjFO955rjmg8GtX7Tumgth4ERy9Ai3Pycu1bt_qxYJntPpahTu8mTEuxoBSTwBQz_0clN0oYwWVF5YoOOZWSMdhDjnuXjxaYvRNiR7sKsXdCLFO2Cqllz04_LP0e_d-iPwYq8HwFgkvWfcux2OsvtUNXbUmoi1fi9UpgPdptxGzLEHGq1465qrI-xX_P8Bv2d6ea</recordid><startdate>20130815</startdate><enddate>20130815</enddate><creator>Han, Bing</creator><creator>Hu, Jia</creator><creator>Shen, Jingyu</creator><creator>Gao, Yonglin</creator><creator>Lu, Yan</creator><creator>Wang, Tian</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20130815</creationdate><title>Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats</title><author>Han, Bing ; Hu, Jia ; Shen, Jingyu ; Gao, Yonglin ; Lu, Yan ; Wang, Tian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-3d16e4b07b28b0097977568734f351f99a7bd272ee9de96bd567f68d132ed3173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>3,4-Dihydroxyphenylacetic Acid - metabolism</topic><topic>adults</topic><topic>animal models</topic><topic>Animals</topic><topic>Apomorphine - pharmacology</topic><topic>Behavior, Animal - drug effects</topic><topic>Brain-derived neurotrophic factor</topic><topic>Chalcone - analogs & derivatives</topic><topic>Chalcone - pharmacology</topic><topic>dopamine</topic><topic>Gene Expression Regulation, Enzymologic - drug effects</topic><topic>Glial cell line-derived neurotrophic factor</topic><topic>Homovanillic Acid - metabolism</topic><topic>Hydroxysafflor yellow A</topic><topic>Male</topic><topic>metabolites</topic><topic>mice</topic><topic>Neostriatum - drug effects</topic><topic>Neostriatum - metabolism</topic><topic>neurons</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>neuroprotective effect</topic><topic>neurotoxicity</topic><topic>Oxidopamine</topic><topic>Parkinson disease</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson Disease - prevention & control</topic><topic>Parkinson's disease</topic><topic>Quinones - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Rotation</topic><topic>Substantia Nigra - drug effects</topic><topic>Substantia Nigra - metabolism</topic><topic>tyrosine</topic><topic>Tyrosine 3-Monooxygenase - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, Bing</creatorcontrib><creatorcontrib>Hu, Jia</creatorcontrib><creatorcontrib>Shen, Jingyu</creatorcontrib><creatorcontrib>Gao, Yonglin</creatorcontrib><creatorcontrib>Lu, Yan</creatorcontrib><creatorcontrib>Wang, Tian</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, Bing</au><au>Hu, Jia</au><au>Shen, Jingyu</au><au>Gao, Yonglin</au><au>Lu, Yan</au><au>Wang, Tian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2013-08-15</date><risdate>2013</risdate><volume>714</volume><issue>1-3</issue><spage>83</spage><epage>88</epage><pages>83-88</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting predominantly the dopaminergic mesotelencephalic system. Enormous progress has been made in the treatment of PD. Our previous study has shown that hydroxysafflor yellow A (HSYA) could attenuate the neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. In the present work, we examined whether HSYA had the neuroprotective effect on dopaminergic neurons of substantia nigra in a rat model of PD. Adult Sprague-Dawley rats were unilaterally injected with 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle. The PD rats were treated with HSYA (2 or 8mg/kg) via caudal vein injection daily for 4 weeks. Rotational tests showed that HSYA significantly attenuated apomorphine-induced turns in 6-OHDA-induced PD rats. HSYA treatment resulted in a significant protection against the loss of tyrosine hydroxylase-positive cells. Our data showed that HSYA also increased the levels of dopamine and its metabolites, glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor in striatum of PD rats. In conclusion, these results supported a role for HSYA in preserving dopamine neuron integrity and motor function in a rodent model of PD, and implied a potential neuroprotective role for HSYA in this disease.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23791614</pmid><doi>10.1016/j.ejphar.2013.06.011</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 2013-08, Vol.714 (1-3), p.83-88 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1660410609 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 3,4-Dihydroxyphenylacetic Acid - metabolism adults animal models Animals Apomorphine - pharmacology Behavior, Animal - drug effects Brain-derived neurotrophic factor Chalcone - analogs & derivatives Chalcone - pharmacology dopamine Gene Expression Regulation, Enzymologic - drug effects Glial cell line-derived neurotrophic factor Homovanillic Acid - metabolism Hydroxysafflor yellow A Male metabolites mice Neostriatum - drug effects Neostriatum - metabolism neurons Neuroprotective Agents - pharmacology neuroprotective effect neurotoxicity Oxidopamine Parkinson disease Parkinson Disease - metabolism Parkinson Disease - prevention & control Parkinson's disease Quinones - pharmacology Rats Rats, Sprague-Dawley Rotation Substantia Nigra - drug effects Substantia Nigra - metabolism tyrosine Tyrosine 3-Monooxygenase - metabolism |
| title | Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T20%3A18%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroprotective%20effect%20of%20hydroxysafflor%20yellow%20A%20on%206-hydroxydopamine-induced%20Parkinson's%20disease%20in%20rats&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Han,%20Bing&rft.date=2013-08-15&rft.volume=714&rft.issue=1-3&rft.spage=83&rft.epage=88&rft.pages=83-88&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2013.06.011&rft_dat=%3Cproquest_cross%3E1660410609%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1429639324&rft_id=info:pmid/23791614&rft_els_id=S0014299913004779&rfr_iscdi=true |